2025
Post-Transcatheter Aortic Valve Replacement Antithrombotic Treatment in Nonindicated Patients Updated Systematic Review and Network Meta-Analysis
Siami S, Kazemian S, Maleki S, Ebrahimi E, Jodeiri F, Ebrahimzade M, Hajiqasemi M, Ebrahimi S, Mehdizadeh M, Aghaei M, Bastan M, Sabet M, Nazari R, Ebrahimi P, Rana J, Nanna M, Giri J, Kolte D, Biering-Sørensen T, Alkhouli M, Hosseini K. Post-Transcatheter Aortic Valve Replacement Antithrombotic Treatment in Nonindicated Patients Updated Systematic Review and Network Meta-Analysis. JACC Advances 2025, 4: 101719. PMID: 40286375, PMCID: PMC12049831, DOI: 10.1016/j.jacadv.2025.101719.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementDual antiplatelet therapyOral anticoagulantsAntithrombotic regimensNetwork Meta-AnalysisAntiplatelet therapyCardiovascular mortalityMyocardial infarctionRisk of all-cause mortalityChronic oral anticoagulationAortic valve replacementMeta-analysisOptimal antithrombotic strategyIncreased risk of mortalityFrequentist network meta-analysisRisk of cardiovascular mortalityChronic obstructive pulmonary diseaseAll-Cause MortalityRisk of mortalityObstructive pulmonary diseaseBleeding riskValve replacementAntithrombotic treatmentNo significant differenceAntithrombotic strategiesAnticoagulants or antiplatelets for secondary prevention of cryptogenic stroke: an updated systematic review and meta-analysis
Chi K, Zarif T, Varrias D, Lee P, Chang Y, Song J, Osabutey A, Borkowski P, Chiang C, Chang Y, Lin Y, Nanna M, Nanna M. Anticoagulants or antiplatelets for secondary prevention of cryptogenic stroke: an updated systematic review and meta-analysis. Heart 2025, 111: 495-505. PMID: 39915077, PMCID: PMC12068992, DOI: 10.1136/heartjnl-2024-325288.Peer-Reviewed Original ResearchPresence of patent foramen ovaleOral anticoagulantsRandomised controlled trialsCryptogenic strokeAtrial cardiopathyIschaemic strokeIschaemic stroke riskSafety of oral anticoagulantsRisk factorsSecondary prevention of cryptogenic strokeStroke riskMeta-analysisOptimal antithrombotic strategyRisk of recurrent ischaemic strokePatent foramen ovaleInteraction p valuePersonalised treatment strategiesSystematic reviewRecurrent ischaemic strokePreventing ischaemic strokeBleeding riskNo significant differenceAntithrombotic strategiesClinical characteristicsForamen ovale
2024
Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis
Yaghi S, Shu L, Fletcher L, Fayad F, Shah A, Herning A, Isho N, Mansour P, Joudi K, Zaidat B, Mahmoud N, Khalek F, Xiao H, Goldstein E, Ghannam M, Siegler J, Omran S, Bakradze E, Nguyen T, Keser Z, Khan M, Shahripour R, de Havenon A, Henninger N, Heldner M, Field T, Aziz Y, Mistry E, Furie K, Engelter S, Markus H. Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis. Stroke 2024, 55: 1776-1786. PMID: 38847098, DOI: 10.1161/strokeaha.124.047310.Peer-Reviewed Original ResearchConceptsCervical artery dissectionSystematic reviewArtery dissectionMeta-analysisBleeding riskIschemic stroke riskAntiplatelet therapyRandomized trialsSpontaneous cervical artery dissectionRisk of deathIschemic strokeCombination of keywordsTreated with antiplateletSafety of dual antiplatelet therapyReducing ischemic strokeSymptomatic intracranial hemorrhageOptimal antithrombotic strategyMajor traumaDual antiplatelet therapyIndividualized therapeutic approachStudy of patientsInclusion criteriaRandomized clinical trialsMeta-analysesEffect size
2018
International survey on anticoagulation and antiplatelet strategies after pediatric liver transplantation
Calinescu AM, Karam O, Wilde JCH, Ansari M, McLin VA, Wildhaber BE. International survey on anticoagulation and antiplatelet strategies after pediatric liver transplantation. Pediatric Transplantation 2018, 23: e13317. PMID: 30393923, DOI: 10.1111/petr.13317.Peer-Reviewed Original ResearchConceptsAntiplatelet strategiesPediatric LTOptimal antithrombotic strategyProspective multicentric trialPediatric liver transplantationAntiplatelet therapyLiver transplantationAntithrombotic strategiesMulticentric trialVascular thrombosisAntiplatelet agentsHepatic arteryLT centersHAT ratePatient weightVascular problemsAnticoagulationFrequent determinantLtInternational surveyPresent surveyOnline surveyThrombosisAnticoagulantsTransplantationChallenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management
Sherwood M, Vora A. Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. Current Cardiology Reports 2018, 20: 130. PMID: 30311013, DOI: 10.1007/s11886-018-1073-9.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementBioprosthetic valve thrombosisPercutaneous coronary interventionAortic valve replacementAntiplatelet therapyValve thrombosisAtrial fibrillationValve replacementPrevent bioprosthetic valve thrombosisPost-transcatheter aortic valve replacementThrombosis managementElective percutaneous coronary interventionOptimal antithrombotic strategyLow-dose ASASmall clinical trialsTreatment of thrombosisSAVR patientsTriple therapyOral anticoagulantsOptimal therapyAortic stenosisAntithrombotic strategiesProlonged DAPTDocumented resolutionAnticoagulation managementAn open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Lopes R, Vora A, Liaw D, Granger C, Darius H, Goodman S, Mehran R, Windecker S, Alexander J. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal 2018, 200: 17-23. PMID: 29898844, DOI: 10.1016/j.ahj.2018.03.001.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionAtrial fibrillationOral anticoagulantsCoronary syndromeNon-Vitamin K Antagonist Oral AnticoagulantsRandomized trialsClinically relevant nonmajor bleedingConcomitant coronary artery diseaseCoronary interventionInternational Society on ThrombosisAntithrombotic therapy strategiesEvaluated ischemic outcomesP2Y12 receptor inhibitionOptimal antithrombotic regimenVitamin K antagonistsProspective randomized trialsRisk of bleedingOptimal antithrombotic strategyMulticenter randomized trialRecurrent ischemic eventsComposite of deathGroup of patientsCoronary artery diseaseBenefit of aspirin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply